top of page

As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis


Readout for newly FDA-approved Amvuttra in a rare heart disease is on many Alnylam investors’ mind. But the company figures patience is a virtue...




Recent Posts

See All

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines. 

We Work For Health. © 2023 All Rights Reserved.

bottom of page